AU2001292667A1 - Immunogenic composition of hepatitis c and methods of use thereof - Google Patents

Immunogenic composition of hepatitis c and methods of use thereof

Info

Publication number
AU2001292667A1
AU2001292667A1 AU2001292667A AU9266701A AU2001292667A1 AU 2001292667 A1 AU2001292667 A1 AU 2001292667A1 AU 2001292667 A AU2001292667 A AU 2001292667A AU 9266701 A AU9266701 A AU 9266701A AU 2001292667 A1 AU2001292667 A1 AU 2001292667A1
Authority
AU
Australia
Prior art keywords
hepatitis
methods
immunogenic composition
immunogenic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292667A
Inventor
David E Clements
Tom Humphreys
Eileen T. Nakano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hawaii Biotechnology Group Inc
Original Assignee
Hawaii Biotechnology Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hawaii Biotechnology Group Inc filed Critical Hawaii Biotechnology Group Inc
Publication of AU2001292667A1 publication Critical patent/AU2001292667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AU2001292667A 2000-09-13 2001-09-13 Immunogenic composition of hepatitis c and methods of use thereof Abandoned AU2001292667A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23092700P 2000-09-13 2000-09-13
US60230927 2000-09-13
PCT/US2001/028767 WO2002022155A1 (en) 2000-09-13 2001-09-13 Immunogenic composition of hepatitis c and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2001292667A1 true AU2001292667A1 (en) 2002-03-26

Family

ID=22867102

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292667A Abandoned AU2001292667A1 (en) 2000-09-13 2001-09-13 Immunogenic composition of hepatitis c and methods of use thereof

Country Status (4)

Country Link
US (1) US6682909B2 (en)
EP (1) EP1326625A4 (en)
AU (1) AU2001292667A1 (en)
WO (1) WO2002022155A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517926D0 (en) * 1995-09-01 1995-11-01 Biocine Spa Binding protein
CN101088561A (en) * 1998-07-21 2007-12-19 展马博联合股份有限公司 Anti hepatitis c virus antibody and uses thereof
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
WO2002072036A2 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
WO2004089978A2 (en) * 2003-04-11 2004-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Use of hcv proteins
US8003332B2 (en) * 2005-05-06 2011-08-23 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of membrane fusion proteins
WO2007128048A1 (en) * 2006-05-02 2007-11-15 The Macfarlane Burnet Institute For Medical Research And Public Health Limited A hepatitis c vaccine delivery vehicle
CA2661814A1 (en) 2006-08-25 2008-02-28 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Recombinant hcv e2 glycoprotein
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
US20110305715A1 (en) * 2010-06-11 2011-12-15 Miao Lynn Y Antibodies to 3-hydroxycotinine and methods of use thereof
US9732121B2 (en) * 2013-09-25 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Rational vaccine design for hepatitis C virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
PL171489B1 (en) 1991-09-13 1997-05-30 Chiron Corp Method of obtaining an immunogenous composition capable to immunologically cross-react with many hcv isolates
PT773957E (en) 1994-07-29 2005-11-30 Chiron Corp HEPATITIS C INNOVATIVE HEPATITIS E1 AND E2 POLYPEPTIDES, AND METHODS OF OBTAINING THEMSELVES
AU716676B2 (en) * 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
NZ508797A (en) * 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof

Also Published As

Publication number Publication date
WO2002022155A1 (en) 2002-03-21
US6682909B2 (en) 2004-01-27
EP1326625A1 (en) 2003-07-16
EP1326625A4 (en) 2005-05-04
US20020119495A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2001255169A1 (en) Carbon nanostructures and methods of preparation
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001234437A1 (en) Deicing compositions and methods of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AP2001002300A0 (en) Hiv immunogenic compositions and methods
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
WO2001041823A8 (en) Radioactive compositions and methods of use thereof
AU2001292667A1 (en) Immunogenic composition of hepatitis c and methods of use thereof
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU2002256543A1 (en) Compositions containing heteropolymers and methods of using same
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU2002221273A1 (en) Delayed and sustained release formulations and method of use thereof
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2962400A (en) Cleaner composition and method of use thereof
AU2001295672A1 (en) Vaccine composition and stabilisation method
AU2001232707A1 (en) Surface tinting composition and method of use
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use